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Abstract-Artemisinin and its derivatives are a promising new class of antimalarial agents containing 
an endoperoxide bridge. [“‘C]Artemisinin alkylated various proteins in uitro. Between 5 and 18% of 
added drug bound to hemoproteins such as catalase, cytochrome c, and hemoglobin. However, it did 
not react with heme-free globin. For catalase and hemoglobin, most of the drug reacted with the protein 
moiety rather than the heme. Artemisinin bound to human serum albumin (HSA) more efficiently at 
pH 8.6 than 7.4, more efficiently in Dulbecco’s PBS than in Tris-HCl buffer, and better when HSA 
had been made fatty acid-free. Dihydroartemisinin also bound to HSA, whereas deoxyartemisinin, an 
inactive derivative, did not. There was no binding between DNA and artemisinin. These data provide 
insight into the mechanism of the reaction between artemisinin and proteins. 
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Artemisinin (qinghaosu), a sesquiterpene endo- 
peroxide, was first isolated in 1972 from Artemisia 
annua, an ancient Chinese herbal remedy for fever 
[l-3]. Since then, artemisinin and its derivatives, 
such as dihydroartemisinin, artemether, arteether, 
and artesunate, have been widely used for the 
therapy of malaria in China, Vietnam, and Burma 
[4]. Over three million doses of artemether have 
been administered in China alone [4]. Artemisinin 
derivatives are particularly useful against chloro- 
quine-resistant Plasmodium falciparum strains and 
cerebral malaria and are currently undergoing phase 
I and phase II clinical studies [4,5]. 
Artemisinin appears to be activated by intra- 
parasitic iron into a free radical, which then acts as 
an alkylating agent. Evidence for the role of free 
radicals includes observations that free radical 
scavengers antagonize the antimalarial activity of 
artemisinin [6-81, the necessity of the endoperoxide 
bridge for antimalarial activity [2,3], as well as the 
observation of an iron-generated free radical by 
electron paramagnetic resonance spectroscopy [9]. 
The catalysis has been demonstrated by cyclic 
voltammetry [lo], and the decomposition products 
have been identified [ 111. The alkylation of proteins 
by artemisinin has also been demonstrated using 
HSA$ [12] and red cell membrane proteins [13] as 
models. The covalent nature of the bond was 
confirmed by electrospray mass spectrometry [12]. 
Heme is also alkylated [14, 151. In this paper, the 
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mechanism of the reaction between artemisinin and 
proteins has been further characterized. 
MATERIALS AND METHODS 
[14C]Artemisinin (45.4 Ci/mol) and deoxy- 
artemisinin were gifts from the Division of 
Experimental Therapeutics, Walter Reed Army 
Institute of Research, Washington, DC. Dihydro- 
artemisinin was a gift from Dr. H. Z. Pan, Institute 
ofBasicMedicalSciences,Beijing, China. Dulbecco’s 
PBS was from Gibco BRL (Grand Island, NY). 
Blood (Type A+) was purchased from the Interstate 
Blood Bank, Memphis, TN. Red blood cell lysate 
was prepared by mixing fresh blood cells with 
hypotonic buffer (10mM NaH2P04, 6.6mM 
Na2HP04, pH 7.4) [16] and then removing mem- 
branes by centrifuging at 11,525g on a micro- 
centrifuge. Bradford protein reagent was purchased 
from Bio-Rad Laboratories (Richmond, CA). 
Artemisinin, bovine liver catalase, horse heart 
cytochrome c, HSA (globin-free), HSA (fatty acid- 
free, globin-free), methemoglobin, salmon testes 
DNA, and all other chemicals were purchased from 
the Sigma Chemical Co. (St. Louis, MO). 
Reactions between artemisinin and proteins. 
Reaction mixtures contained 1 mg/mL of the 
appropriate protein and 11 nCi/mL [14C]artemisinin 
in PBS (pH 7.4). Control reaction mixtures lacking 
protein were carried out in tandem under identical 
conditions. After 24 hr incubations at 37”, a 500 PL 
aliquot from each mixture was applied to an NAP- 
5 size-exclusion column (Pharmacia, Uppsala, 
Sweden) preequilibrated in PBS, pH 7.4. The protein 
content of the eluate was determined by the method 
of Bradford [17]. High and low molecular weight 
material separated with the initial 0.9 mL eluate and 
the subsequent 3 mL eluate, respectively. A 100 PL 
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Table 1. Binding of [14C]artemisinin to various proteins and to DNA 
Target pmol bound/mg protein Percent radioactivity bound 
Albumin (fat-free, globin-free) 41.8 zt 1.3 10.9 + 0.4 
Albumin (giobin-free) 8.5 -e 0.9 2.4 + 0.3 
Catalase 23.9 rt 1.6 8.3 2 0.4 
Cytochrome c 14.3 ic 0.9 4.8 f 0.4 
Globin 3.7 1: 0.8 1.6 ” 0.3 
Methemoglobin 43.7 rL: 8.2 18.2 + 3.4 
Red cell lysate 20.0 k 2.7 8.3 k 1.1 
DNA 1.5 c 0.2 0.6 k 0.1 
Values are means + SD. N = 3. 
aliquot of each fraction was counted in 7 mL 
Scintiverse BD (Fisher Scientific, Fair Lawn, NJ) on 
a Beckman LS 7000 Scintillation Counter. 
Extraction of heme and heme adducts. [14C]- 
Artemisinin-labeled erythrocyte lysate and catalase 
were both prepared as described above. The heme 
and protein moieties were separated by a modification 
of the method of Fuhrhop and Smith [lS]. Aliquots 
of 5OOpL were mixed with 10mL ethyl acetate, 
followed by SOOpL of glacial acetic acid/saturated 
Na2S04 (4: 1) in a glass tube. The tubes were 
inverted, an equal volume of 1% Na2S04 was added, 
and the mixtures were shaken briefly by hand. The 
tubes were allowed to sit until the mixtures separated 
into two layers. The organic layer contained more 
than 99% of the total heme, and no detectable heme 
was left in the aqueous phase as determined by the 
pyridine hemochromogen assay [18]. Both layers 
were recovered and counted separately as described 
above. 
Buffer and pH eflectv on binding of artemtsinin 
and der~oati~es to albumin. HSA (1 mg) was dissolved 
in 1 mL of each of the following buffers: PBS 
(pH 7.4); PBS (pH 8.6); Tris (150 mM, pH 7.4); and 
Tris (150 mM, pH 8.6). Unlabeled artemisinin, 
dihydroartemisinin, or deoxyartemisinin was added 
to a final concentration of 1 mM from a 10 mM 
ethanolic stock solution. Controls lacking protein 
were prepared simult~eously. Mixtures were 
incubated at 37” for 24 hr. Proteins were separated 
from free drug by four spins through Centricon- 
microconcentrators (Amicon Division, W.R. Grace 
& Co., Beverly, MA). Concentrates were recovered 
and diluted to a protein concentration of 1 mg/mL. 
Spectra were obtained on a Hewlett Packard model 
8452 Spectrophotometer. 
RESULTS 
[14C]Artemisinin bound covalently to various 
proteins (Table 1). Up to 18% of the total label 
eluted in the high molecular weight fraction that 
contained >QQ% of the total protein. In the absence 
of protein, < 1% of the added radioactivity eluted 
in this fraction. 
All of the hemoproteins tested bound artemisinin. 
Catalase and cytochrome c bound 8 and 5%, 
respectively, of added drug. Methemoglobin bound 
the most drug, 18% of the total. Fresh blood lysates, 
Table 2. Percentage of protein-associated [14C]artemisinin 






20.0 f 0.6 
18.3 f 0.3 
8.5 sr. 0.1 
Values are means f SD, N = 3. 
which consist predominantly of reduced hemoglobin, 
bound only 8% of total radioacti~ty. In contrast, 
heme-free globin bound negligible amounts of drug 
(1.6%). 
HSA only bound a very small percentage (2.4%) 
of radioactive artemisinin. However, fatty acid-free 
HSA bound substantially more drug (ll%), 
suggesting that artemisinin can bind and react in the 
hydrophobic pocket of the protein. There was no 
binding to DNA (less than 1%). 
To determine whether the hemoprotein-bound 
[14C]artemisinin is associated with protein or heme, 
the protein and heme moieties were separated by 
extraction (Table 2). For both hemoglobin and 
catalase, only approximately 20% of the protein- 
associated radioacti~ty was recovered in the ethyl 
acetate layer, which contained >QQ% of the original 
heme content. When artemisinin-labeled HSA 
(which does not contain heme) was used as a control 
for this extraction, 8% of total radioactivity was 
detected in the ethyl acetate layer. These data 
suggest that when hemoglobin and catalase are 
alkylated, most of the drug becomes attached to the 
protein moiety. 
The reaction between artemisinin and HSA was 
pH and buffer dependent (Fig. 1). Artemisinin- 
bound HSA had a distinct absorption peak at 306 nm. 
The area of the peak reflected the relative amount 
of alkylated protein, since it increased with reaction 
time (data not shown). Reactions at pH 7.4 in either 
PBS or Tris buffer were less efficient than in the 
corresponding pH 8.6 buffer. The reaction of 
artemisinin with HSA, therefore, is favored at high 
pH. Reactions in PBS at both pH 7.4 and 8.6 were 
more efficient than in Tris at the same pH levels. 
To better understand the binding of artemisinin 














Fig. 1. Effects of pH and buffer on the absorption spectra of artemisinin-HSA adducts. HSA was 
incubated with 1 mM artemisinin for 24 hr and then separated from free drug as described in Materials 
and Methods. Incubations were performed in PBS, pH 7.4 (- -); PBS, pH 8.6 (----); Tris, pH 7.4 
(-); and Tris, pH8.6 (------). 
to HSA, two derivatives of artemisinin, dihydro- 
artemisinin and deoxyartemisinin, were also used to 
study binding (Fig. 2). Artemisinin appeared to be 
more reactive than either derivative. However, 
there was a definite reaction between HSA and 
dihydroartemisinin, an active artemisinin derivative. 
The endoperoxide bridge appears to be necessary 
for the reaction since deoxyartemisinin, an inactive 
derivative. did not react with HSA. 
DISCUSSION 
Artemisinin has been shown previously to form 
covalent adducts with HSA [12], red cell membrane 
proteins [13], and heme [14,15]. Heme and iron 
catalyse the decomposition of artemisinin into 
reactive free radicals [lo] and electrophiles [ll], 
which could act as alkylating agents. This could 
explain the selective toxicity of artemisinin derivatives 
to malaria, since malaria parasites have high 
intracellular stores of heme. These reactions could 
also explain some of the adverse effects of the drug 
[ 191. However, both iron-dependent and independent 
reactions between artemisinin and HSA have been 
observed [12]. Thus, further work was needed to 
define the role of heme and iron as catalysts for 
protein alkylation. 
In the present study, hemoproteins, such as 
hemoglobin, catalase, and cytochrome c, were found 
to react quite well with artemisinin. Most of the 
hemoglobin- or catalase-bound radioactivity was 
associated with the protein moiety rather than the 
heme. Yet heme-free globin did not react with 
artemisinin. These data suggest that in hemoproteins 
heme catalyses the alkylation of the protein moiety. 




Fig. 2. Absorption spectra of HSA after reaction with artemisinin (-----), dihydroartemisinin (------), 
deoxyartemisinin (- -), and in the absence of drug (-). HSA was incubated with 1 mM 
concentrations of the drugs for 24 hr in Tris buffer (pH 8.6) and then separated from free drug as 
described in Materials and Methods. 
Many alkylating agents target DNA [20]. Thus, it 
was necessary to determine whether artemisinin 
might act in this manner. However, the lack of 
reactivity between artemisinin and DNA suggests 
that DNA alkylation is not an important part of the 
mode of action of the drug. 
HSA binds noncovalently to many drugs and small 
molecules, including fatty acids [21,22]. The binding 
of one compound is often influenced by the binding 
of a second compound, either by direct competition 
or by an allosteric interaction [22]. For example, 
fatty acids have been shown to inhibit the binding 
of dansylsarcosine by direct competition [23] and of 
diazepam allosterically [24,25]. The fact that more 
HSA is alkylated by artemisinin when it is fatty acid- 
free suggests that the drug may be binding at the 
fatty acid binding site, or a site that is allosterically 
regulated by fatty acid binding. 
The reaction between artemisinin and HSA 
occurred faster at higher pH. There are two possible 
explanations for this. First, artemisinin may 
decompose spontaneously at alkaline pH into a 
diketone that might be reactive with amino acids 
[26]. A second explanation is that protein amino 
groups become unprotonated at higher pH levels 
and are, therefore, better nucleophiles. Nucleophilic 
amines may also explain why the reaction proceeds 
better in PBS than in Tris buffer at identical pH, 
because the amino group in Tris may compete for 
the reaction with artemisinin. 
Dihydroartemisinin is an important analog of 
artemisinin. It is the principle active metabolite of 
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the three most important artemisinin derivatives in 
clinical use-artemether, arteether, and artesunate 
[4]. We have demonstrated previously that both 
artemisinin and dihydroartemisinin form covalent 
adducts with HSA [12]. Here we show that 
artemisinin forms a chromophore with HSA at a 
faster rate than dihydroartemisinin. This suggests 
either that the presence of a lactone moiety increases 
the reaction efficiency or that the dihydroartemisinin- 
HSA chromophore has a different structure than the 
artemisinin-HSA chromophore. In contrast, no 
chromophore forms when deoxyartemisinin is 
incubated with HSA, suggesting that there is no 
reaction. This implies that the endoperoxide bridge, 
which is necessary for antimalarial activity, is 
necessary for protein alkylation. 
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